CytomX Therapeutics Announces New Employment Inducement Grant
2020年3月26日 - 5:02AM
CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage
oncology-focused biopharmaceutical company pioneering a novel class
of investigational antibody therapeutics based on its Probody®
therapeutic technology platform, today announced that on March 23,
2020, the Company granted its recently appointed senior vice
president and chief financial officer, Carlos Campoy, an option to
purchase a total of 350,000 shares of the Company’s common stock at
an exercise price per share equal to $4.93, which was the closing
trading price on March 23, 2020, the date of the grant.
The stock options were granted pursuant to the
Company’s 2019 Employment Inducement Incentive Plan, which was
approved by the Company’s board of directors in September 2019
under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants
to induce new employees to enter into employment with the
Company.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused
biopharmaceutical company with a vision of transforming lives with
safer, more effective therapies. We are developing a novel class of
investigational antibody therapeutics, based on our Probody
technology platform, for the treatment of cancer. As leaders in the
field, our innovative technology is designed to turn previously
undruggable targets into druggable targets and to enable more
effective combination therapies. CytomX and its partners, comprised
of leading biotechnology and pharmaceutical companies, have
developed a robust pipeline of potential best-in-class
immunotherapeutic candidates against clinically validated targets
and potential first-in-class therapeutic candidates against novel,
difficult to drug targets. Five novel drug-candidates utilizing our
Probody technology are in the clinic, with three in Phase 2 studies
and two in Phase 1 studies. These clinical programs include cancer
immunotherapeutic candidates against validated targets such as a
PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072)
and two CTLA-4-targeting Probody therapeutics partnered with
Bristol-Myers Squibb (BMS-986249) and (BMS-986288). The CytomX
clinical stage pipeline also includes first-in-class Probody drug
conjugate product candidates against previously undruggable
targets, including a CD166-targeting Probody drug conjugate wholly
owned by CytomX (CX-2009) and a CD71-targeting Probody drug
conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among
cancer targets that are considered to be inaccessible to
conventional antibody drug conjugates due to their presence on many
healthy tissues. In addition to its wholly owned programs, CytomX
has strategic collaborations with AbbVie, Amgen, Astellas and
Bristol-Myers Squibb. For additional information about CytomX
Therapeutics, visit www.cytomx.com and follow us on LinkedIn and
Twitter.
PROBODY is a U.S. registered trademark of CytomX Therapeutics,
Inc.
Contact:
Investors and Media:
Christopher Keenan VP, Investor Relations and Corporate
Communications ckeenan@cytomx.com 650-383-0823
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 8 2024 まで 9 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 9 2023 まで 9 2024